Publications

15 Feb 2018
News

Does CVS–Aetna Spell the End of Business as Usual?

January 1994 (Revised July 1998)
Case

Repligen Corporation: January 1992

By: Josh Lerner and David Kane

Sandford Smith, CEO of Repligen, faces the breakdown of negotiations about a proposed joint venture with a large pharmaceutical firm. He must decide whether to proceed using his firm's internal resources or whether to seek to revise the proposed collaboration. If the... View Details

Keywords: Joint Ventures; Decisions; Contracts; Agreements and Arrangements; Value

11 May 2011
News

Clinical Registries: The Opportunity For The Nation

August 2013 (Revised October 2013)
Case

MedImmune Ventures

By: Richard G. Hamermesh and David Lane

Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details

Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; Australia; Europe; London

April 2009 (Revised November 2012)
Case

Sermo, Inc.

By: Thomas R. Eisenmann and Lars Peter Christian Nielsen

Sermo operates the leading online professional network for physicians in the United States. Doctors use Sermo free of charge to post surveys regarding diagnostic and treatment concerns and to discuss these concerns, as well as challenges with managing their practices.... View Details

Keywords: Entrepreneurship; Health Care and Treatment; Knowledge Sharing; Two-Sided Platforms; Conflict and Resolution; Social and Collaborative Networks; United States

August 2003 (Revised August 2006)
Case

New Sector Alliance (A): An Entry into Health Care?

By: Regina E. Herzlinger, Stacy Smollin Schwartz and Jeffrey Cronin

Describes the structure of the U.S. health care system and presents a study of a nonprofit consulting firm that hopes to enter the health care system. Includes descriptions of hospitals, doctors, insurers, medical technology providers, medical devices, pharmaceuticals,... View Details

Keywords: Health; Health Care and Treatment; Health Disorders; Nonprofit Organizations; Health Industry; United States

Find at Harvard

Awards

Dan and Mary Lou Schendel Best Paper Prize

By: Rebecca M. Henderson

Won the 2010 Dan and Mary Lou Schendel Best Paper Award from the Strategic Management Society for her paper with Ian Cockburn, "Measuring Competence? Exploring Firm Effects in Pharmaceutical Research" (Strategic Management Journal, 1994). The award is for a... View Details

January 2001 (Revised May 2003)
Case

Novartis Pharma: The Business Unit Model

By: Srikant M. Datar, Carin-Isabel Knoop and Cate Reavis

In June 2000, Novartis reorganized its pharmaceutical business to form global business units in oncology, transplantation, ophthalmology, and mature products. The remaining primary care products continued to be managed within global functions (e.g., R&D and marketing).... View Details

Keywords: Restructuring; Recruitment; Product Marketing; Organizational Structure; Problems and Challenges; Pharmaceutical Industry; Pharmaceutical Industry

Research Summary

AIDS in Africa: Life, Death and Property Rights

By: Debora L. Spar

In the final years of the twentieth century, the world was hit by a plague of epidemic proportions--the plague of AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought... View Details

March 2008 (Revised March 2022)
Case

Cadbury Schweppes: Capturing Confectionery (A)

By: David Collis, Toby Stuart and Troy Smith

In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details

Keywords: Business History; Strategy; Decision Choices and Conditions; Mergers and Acquisitions; Food and Beverage Industry

26 Feb 2012
News

Can brand Mallya make Kingfisher Airlines fly?

Article

One Obstacle to Curing Cancer: Patient Data Isn't Shared

By: Richard G. Hamermesh and Kathy Giusti

Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For... View Details

Keywords: Healthcare; Technological And Scientific Innovation; Cancer Care In The U.S.; Cancer Treatment; Precision Medicine; Personalized Medicine; Data Sharing; Technological Innovation; Analytics and Data Science; Health Disorders; Medical Specialties; Research and Development; Customization and Personalization; Health Industry; United States

Register to Read

26 Mar 2018
News

She Was Given Three Years To Live. So She Transformed Cancer Research

February 1996
Case

Chadwick, Inc.: The Balanced Scorecard (Abridged)

By: Robert S. Kaplan

The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details

Keywords: Balanced Scorecard; Research and Development; Product Launch; Commercialization; Consumer Behavior; Customer Focus and Relationships; Performance Evaluation; Pharmaceutical Industry

06 Jan 2021
News

Covid-19 Case Studies Make Their Way Into M.B.A. Curricula

April 18, 2022
Article

Will mRNA Technology Companies Spawn Innovation Ecosystems?

By: Christoph Grimpe, Timo Minssen, W. Nicholson Price, II and Ariel Dora Stern

The mRNA technologies that helped rapidly create effective COVID-19 vaccines could become technology platform businesses, which has tremendous implications for players in the world of drug development. These platforms could attract other companies interested in... View Details

Keywords: Health Care; Digital Health; Technology; Innovation; Health Care and Treatment; Technological Innovation; Digital Transformation; Health Industry; United States

Register to Read

February 2007 (Revised April 2010)
Case

Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics

By: Robert S. Huckman, Gary P. Pisano and Mark Rennella

Describes the reorganization of the drug discovery organization at Wyeth Pharmaceuticals and focuses on the decisions to: (1) centralize decision-making within drug discovery and (2) institute numerical metrics--jointly affecting all R&D scientists--for the progression... View Details

Keywords: Decision Making; Measurement and Metrics; Business Processes; Organizational Structure; Research and Development; Science-Based Business; Creativity; Pharmaceutical Industry

March 1994 (Revised April 1994)
Case

Eli Lilly and Co.: The Flexible Facility Decision--1993

By: Gary P. Pisano

In 1993, Eli Lilly is preparing to build manufacturing capacity for three new pharmaceutical products that it expects to launch in 1996. Management wrestles with a decision of whether to add specialized manufacturing capacity or flexible capacity. This question touches... View Details

Keywords: Debates; Cost vs Benefits; Decisions; Investment; Goals and Objectives; Product Launch; Production; Corporate Strategy; Pharmaceutical Industry